Skip to content
Review Open access

Artificial Intelligence in Cardiovascular Risk Prediction: An Up-to-Date Narrative Review on the Emerging Role of Lipid Profile-Based Models

Aug 2026 · Journal of Clinical Medicine · Vol 15, pp. 6053 · 0 citations · 48 references
Medicine

TL;DR

A narrative review summarizes evidence on artificial intelligence (AI)-based cardiovascular risk assessment, focusing on lipid profile-based and multimodal models incorporating lipid-related variables incorporating lipid-related variables.

Abstract

Introduction: Cardiovascular risk prediction remains challenging, particularly in patients with intermediate risk, mixed dyslipidemia, elevated lipoprotein(a), or variable lipid profiles. Conventional risk calculators may not fully capture nonlinear relationships among lipid, clinical, imaging, and longitudinal data. Objectives: This narrative review summarizes evidence on artificial intelligence (AI)-based cardiovascular risk assessment, focusing on lipid profile-based and multimodal models incorporating lipid-related variables. Methods: PubMed/MEDLINE, Scopus, and Google Scholar were searched for English-language articles published up to January 2026. Original studies, reviews, and relevant clinical guidelines addressing AI-based cardiovascular risk models, lipid-related predictors, and clinically applicable approaches were considered. Results: Lipid profile-based AI models may identify lipid phenotypes and lipid-related patterns associated with increased cardiovascular risk, while multimodal models have shown improved performance in selected datasets. However, the reviewed studies address heterogeneous tasks, including phenotype classification, cardiovascular event prediction, mortality prediction, patient trajectory modeling, and absolute risk estimation. Most evidence remains retrospective, with limited external validation, calibration assessment, and clinical utility data. Conclusions: AI-based models may support cardiovascular risk assessment, but routine implementation requires prospective validation, standardized evaluation, calibration, explainability, and clinical impact studies.

Read PDF

Similar papers

Review Aug 2026

Artificial intelligence for risk prediction in atherosclerotic cardiovascular disease: A narrative review of advances, validation challenges, and clinical translation (2020-2026).

Future work should prioritize calibration, robustness, transportability, fairness, interpretability, regulatory clarity, workflow integration, and prospective evidence of decision impact or post-deployment benefit, as well as major barriers remain.

Rui-Feng Liu, R. Arena, V. Vasile et al. · 0 citations
Open access Aug 2026

Integration of lipidomic and polygenic risk scores within contemporary clinical cardiovascular risk assessment pathways: a multi-cohort development and validation study

This investigation investigated whether selective integration of lipidomic and genomic risk signals into AusCVDRisk improves 5-year CVD prediction and reclassification, with a focus on individuals at intermediate clinical risk.

Aleksandar Dakic, Jing-Qin Wu, Ting-Ting Wang et al. · 0 citations
Review Open access Oct 2026

A machine learning-derived aging index for risk stratification and mortality prediction in cardiovascular-kidney-metabolic syndrome: A retrospective cohort study

Background The cardiovascular‑kidney‑metabolic (CKM) syndrome shows substantial heterogeneity in progression, yet existing biological age indices are not tailored to CKM pathways. We developed an aging index (CKMAI) using machine learning and evaluated its predictive performance for mortality and high‑risk CKM status....

Zheng-Yang Zhu, Ke-Jun Ren, Dong Wang et al. · 0 citations
Review Sep 2026

Artificial Intelligence–Driven Prediction and Management of Chronic Diseases: A Comparative Analysis of Diabetes, Cardiovascular Disease, and Cancer

Artificial intelligence (AI) is increasingly used to convert heterogeneous clinical data into actionable predictions across chronic disease pathways, yet the maturity and clinical role of AI differ substantially among diabetes, cardiovascular disease (CVD), and cancer. This structured comparative evidence synthesis eva...

Reshmi Gopalakrishnan · 0 citations
Open access Aug 2026

Metabolomic profiling refines cardiovascular risk stratification beyond SCORE2-diabetes in patients with concurrent type 2 diabetes and pulmonary dysfunction

In participants with T2D and LFI, adding a metabolomic signature to SCORE2-Diabetes produced a statistically significant but moderate improvement in risk discrimination, which supports further evaluation in independent cohorts and prospective impact studies.

Mei-Li Li, Yan-Yan Shen, You-Wei Huang et al. · 0 citations
#federated learning Review Open access Sep 2026

Machine learning-based risk prediction models for type 2 diabetes in primary care: a scoping review

Evidence on ML-based risk prediction models for T2DM applicable to primary care remains limited despite growing interest in AI for diabetes prediction; greater emphasis is needed on external validation, calibration, prospective implementation, and evaluation across diverse primary care populations before widespread cli...

Rashita Ravi, J. Olickal · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.